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Thymomas are rare neoplasms arising from the epithelial cells in
the thymus gland; they represent the most frequent tumours of the
anterior mediastinum. Their estimated incidence in Italy is about
0.13/100 000 new cases every year (Verdecchia et al, 1997; Decarli
et al, 1998). Thymomas are usually slow growing and have benign-
appearing histological findings (Pollak et al, 1992). The malignant
behaviour is not based on histological criteria but on macroscopic
and microscopic signs of invasiveness. The presence of invasion is
considered to be the single most important factor predictive for
future behaviour (Verley et al, 1985; Maggi et al, 1986) and forms
the basis for the most widely used clinical staging system described
by Masaoka (1981). Among patients with invasive thymoma, prog-
nosis has been directly related to clinical Masaoka stage and to 
the ability to perform a complete excision (Maggi et al, 1991).
Conversely, considerable controversies exist regarding the impor-
tance of other potential prognostic factors, namely the presence of
associated autoimmune disorders, and the histological subtype
(Lewys et al, 1987; Pescarmona et al, 1990).
The majority of patients are diagnosed with an encapsulated or
non-invasive tumour, while 35–40% have locally advanced or
metastatic disease (Maggi et al, 1991). Complete surgical resec-
tion is a successful treatment especially in the absence of signifi-
cant infiltration of the surrounding tissue, yelding to a less than 5%
recurrence rate (Maggi et al, 1991; Kohmann, 1997; Schmidt et al,
1997). Surgery is the treatment of choice also in patients with
locally advanced disease and should be performed whenever
possible (Yagi et al, 1996), even in cases of disease recurrence
(Kirschner, 1990; Maggi et al, 1991). Locally advanced thymomas
tend to recur after complete resection, therefore adjuvant radio-
therapy is often prescribed, although further studies are needed to
confirm its benefit (Curran et al, 1988; Urgesi et al, 1992). In
large, invasive thymomas, with invasion of major vessels or
cardiac structures, complete resection is more difficult to achieve
and, despite the improvement of surgery techniques, radical resec-
tion is reportedly feasible only in a half of cases bearing stage III
and hardly ever in those with stage IV (Maggi et al, 1991).
The role of chemotherapy is controversial and usually confined
to patients developing recurrent disease after surgery and radio-
therapy (Kohmann, 1997). A few single-institution experiences
(Giaccone et al, 1985; Fornasiero et al, 1991; Macchiarini et al,
1991) and two intergroup studies (Loeher et al, 1994; Giaccone et
al, 1996) including small groups of patients with local recurrence
or distant metastases suggest that cisplatin containing regimens are
active with an overall response rate ranging from 50% to 80%.
These promising data suggest testing chemotherapy in a
neoadjuvant setting in order to improve the resection rate of
patients with locally advanced disease. Six reports of primary
chemotherapy followed by surgery in a total of 61 patients have
been reviewed by Tomiak and Evans (1993). Forty-nine patients
received a cisplatin-based regimen. The overall response to
chemotherapy was 89%, with 19 complete remissions and 35
partial remissions. Twenty-two patients underwent surgery, and in
11 patients a complete resection was achieved – all 11 had been
treated with a cisplatin-based regimen. Following the interesting
results obtained in the largest series ever published from a single
institution with the association of cisplatin, doxorubicin,
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Correspondence to: L Dogliottivincristine and cyclophosphamide (ADOC), which reported a
response rate of 92% in 37 advanced/metastatic patients
(Fornasiero et al, 1991), we evaluated the ADOC scheme as
preoperative chemotherapy in patients with stage III and IVa
thymoma.
PATIENTS AND METHODS
Selection criteria
Patients presenting in our institution with locally advanced non-
metastatic thymomas judged not amenable to surgical resection
with radical intent, were considered in the present analysis.
Eligibility criteria included: histological proof of thymoma, age
less than 75 years, no history of malignancy other than basal cell
carcinoma of the skin or in situ cervical cancer; measurable
disease, performance status of 0–2 according to the ECOG
(Eastern Cooperative Oncology Group) scale, adequate bone
marrow reserve (leucocyte count > 3500 mL–1, platelet count 
>100 000/mL–1) and liver (bilirubin <1.5 mg dl–1) and renal (serum
creatinine <1.5 mg dl–1, creatinine clearance >65 ml min–1) func-
tion. Patients with local recurrent disease after radical surgery
were also included. Exclusion criteria were the following: active
angina pectoris, congestive heart failure, previous myocardial
infarction, impaired ventricular ejection fraction, previous
chemotherapy and/or radiation therapy, metastatic disease.
The pretreatment staging procedures included history and
physical examination, chest X-ray, screening chemistries, electro-
cardiogram (ECG), computed tomography (CT) of the chest and
abdomen, and anterior mediastinotomy with mediastinal resection
biopsy. Other radiological investigations were performed, if neces-
sary, to best estimate tumour extension.
Thymomas were classified according to the predominant cell
type (Lewis et al, 1987): (a) lymphocytic, (b) epithelial, (c) mixed
lympho-epithelial, (d) spindle cell. Stage was assessed according
to Masaoka classification (Masaoka et al, 1981) as follows: I,
macroscopically completely encapsulated; II, microscopic inva-
sion into capsule and/or macroscopic invasion into surrounding
fatty tissue, mediastinal pleura, and both; III, macroscopic inva-
sion into contiguous viscera structure; IVa, pleural or pericardial
dissemination; IVb, lymphogenous or hematogenous metastases.
Treatment administration and response evaluation
Treatment consisted of intravenous administration of adriamycin
(40 mg m–2) and cisplatin (50 mg m–2) given on day 1, vincristine
(0.6 mg m–2) on day 2 and cyclophosphamide (700 mg m–2) on day
4 (ADOC). This scheme was repeated every 3 weeks. A chest
radiography was planned after two chemotherapy courses, while a
complete re-staging including CT scan of the chest and upper
abdomen was performed after four cycles.
Response was assessed in accordance with the World Health
Organization (WHO) criteria (Miller et al, 1981). Complete remis-
sion (CR) was defined as complete disappearance of all clinical,
radiological and biochemical evidence of disease for a minimum
of 1 month. Partial response (PR) was defined as a 50% or greater
reduction in the sum of the product of the largest diameter and its
perpendicular of all measurable lesions that lasted at least 4 weeks.
Progressive disease (PD) was defined as an increase of at least
25% in the size of measurable lesions or the development of new
lesions. Toxicity was graded according to the WHO criteria
(Miller et al, 1981).
All patients with clinical CR or PR were addressed to surgery.
Surgery was planned to be performed 3 or 4 weeks after the 4th
chemotherapy cycle. In case of disease response but with the
residual mass not amenable to surgery with radical intent, further
chemotherapy was administered up to a maximum of six cycles.
Resection was defined as radical if all macroscopic disease was
removed and all surgical margins were free of tumour. Patients
with malignant cells at post-operative histology received radio-
therapy (45 Gy in fractionated doses) followed by two further
ADOC cycles. Radiotherapy was planned instead of surgery in
case of no response or in the presence of inoperable residual
disease after chemotherapy.
Time to progression was measured from the start of
chemotherapy until progression. Survival duration was measured
from the date of treatment start until the day of death or last
follow-up visit. Survival curves were plotted by the Kaplan–Meier
technique and comparison was performed using the log-rank test.
Statistical analysis was performed on an IBM-compatible personal
computer using the SPSS-PC software (Nie et al, 1988).
RESULTS
From October 1990 to November 1997, 16 consecutive patients
(nine males and seven females) with stages III–IVa invasive
thymoma entered the study. The clinical characteristics are listed
in Table 1. Thirteen patients were evaluated at first diagnosis,
while three were at first local relapse of disease 30, 42 and 85
months after radical surgery. No patients showed myasthenia
gravis, lupus erythematosus, pure red aplasia or hypogamma-
globulinaemia. One patient showed amenorrhea in association
with steatorrhea, lasting one year prior to the thymoma detection.
Sixty-eight ADOC cycles were delivered (median 4, range 2–6).
Toxicity was acceptable, nausea/vomiting, leukopenia and
anaemia were the most frequent toxic events encountered, but
were moderate in almost all patients. Only two patients displayed
grade III leukopenia and one patient grade III nausea/vomiting.
Anti-emetic treatment was metoclopramide in five patients and
5HT3 antagonists in the remaining 11. None of the patients on
study received colony-stimulating factors (G-CSF or GM-CSF) or
epoetin.
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Table 1 Patient characteristics
No. 16
Males 9 (56.2%)
Females 7 (43.7%)
Age median (range) 55 (28–69)
ECOG performance status
0 5 (31.2%)
1 10 (62.5%)
2 1 (6.3%)
Histology
Lympho-epithelial 12 (75.0%)
Epithelial 2 (12.5%)
Spindle cell 2 (12.5%)
Stage
III 10 (62.5%)
IVa 6 (37.5%)
Previous surgery 3 (18.7%)Dose reduction of all four drugs was performed in two patients
due to leukopenia. Cisplatin only was reduced in one patient
developing renal toxicity. Treatment delays (1 week) was
performed in eight patients due to haematological toxicity. None
of the patients interrupted treatment early due to toxicity.
Treatment outcome of each patient is listed on Table 2. One patient
attained a CR and 12 patients attained a PR, for an overall response
rate of 13/16 (81.2%). Two patients showed a SD and only one
progressed. Two patients: no. 9 and no. 13, received only three and
two ADOC cycles, due to patient refusal and progressive disease
respectively. The patient (no. 15) who achieved a CR after four
chemotherapy cycles refused surgery and was addressed to radio-
therapy. A disease recurrence occurred 2 months later leading to
the patient’s death.
Of 12 cases attaining a PR after four chemotherapy cycles, nine
underwent radical surgery (five out of ten with stage III, and four
out of six with stage IVa) and became disease free. Residual
disease was observed in eight cases, while fibrosis was detected in
one case. Two patients with PR and two with SD, at the end of the
4th cycle, were judged not operable with radical intent and
received two further ADOC cycles, but afterwards they were still
considered not amenable to surgery. Radiotherapy, either in adju-
vant setting or instead of surgery, was performed in 13 patients, but
was not performed in one case (no. 8) due to the absence of micro-
scopic residual disease at post-chemotherapy surgery, and in the
remaining two cases (nos 13 and 14) due to the rapid deterioration
of the general condition as a consequence of progressive disease
occurring after two and five ADOC cycles respectively.
The last date of follow-up was 15 September 1998, and at the
time of writing nine patients have shown a disease progression and
died of disease, while seven patients are still alive and disease free.
Median disease-free interval (Figure 1A) and overall survival
(Figure 1B) were 33.2 and 47.5 months respectively. Disease
response to chemotherapy was associated with a relatively long
survival prospect (median 57.2 months), whereas non-responding
cases had a poor prognosis (median survival 12.5 months) (P <
0.01). Among the nine patients attaining the disease-free status
after chemotherapy + surgery, progression occurred in four, while
four cases survived more than 5 years (nos 4, 6, 8 and 12) (Table
2). The best outcome was observed in the patient obtaining a
pathological complete response (fibrosis post-chemotherapy
histology), who is still alive and disease-free after 8 years.
DISCUSSION
Debulking surgery followed by radiotherapy is a well-recognized
form of treatment in non-radically resectable invasive thymoma
(Urgesi et al, 1992; Kohmann, 1997). Since thymoma is a
chemosensitive neoplasm (Fornasiero et al, 1991; Macchiarini et
al, 1991; Loeherer et al, 1994; Giaccone et al, 1996) it is logical to
evaluate chemotherapy as a potential adjunct to surgery and radio-
therapy in this clinical setting.
ADOC is the combination regimen most frequently used in Italy
(Fornasiero et al, 1991). As a preoperative approach, in the Padua
experience (Rea et al, 1993), it was found to be able to obtain a
100% response rate in 16 cases, 11 of them attaining a radical
operation.
In the present series, the ADOC regimen confirmed its great
activity with a response rate of 81%. The first six cases have been
already described in a preliminary report by our group (Berruti et
al, 1993). Patients obtaining a disease response to chemotherapy
showed a consistent survival advantage in comparison to no-
responders. It is well known that this difference may be unrelated
to treatment and cannot be used for inferences about treatment
effectiveness (Anderson et al, 1983); at any rate, these data suggest
that response is a useful marker to predict patients destined to have
a good prognosis.
It is known that the long-term survival rate of patients with
locally advanced thymoma is mainly dependent on the possibility
to attain a disease free status. The survival of stage III patients
radically resected is similar, in fact, to that of stage II patients
(Maggi et al, 1991). The resection rate represents, therefore, a
surrogate parameter of treatment efficacy for patients submitted to
primary chemotherapy. The per cent of patients attaining a disease-
free status in our series was close to that reported elsewhere with
the same scheme (Rea et al, 1993).
As mentioned in the introduction, about 50–60% of stage III
cases can be radically resected, but no patients with stage IVa can
benefit from surgery (Maggi et al, 1991). In the present experi-
ence, five out of ten cases with stage III, and four out of six with
stage IVa, judged inoperable before chemotherapy, were radically
resected. It is noteworthy that four ADOC cycles are sufficient to
obtain the maximum results in terms of resection rate, as no
patients judged unresectable after four cycles became resectable
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Figure 1 Disease-free survival (A) and overall survival (B) in patients with
locally advanced thymomas, submitted to primary chemotherapyafter two further courses. These data suggest that primary
chemotherapy can improve the resection rate of locally advanced
thymomas, but a larger number of patients and randomized trials
are needed to this suggestion. Unfortunately, due to the rarity of
the disease, such trials are very difficult to perform. In our hands,
the ADOC combination regimen led to a low CR rate: 2/16
(12.5%), one clinical and one pathological. The patient attaining a
clinical CR refused surgery and showed a disease progression after
a few months, whereas the patient with pathological CR is still
alive and disease-free more than 8 years after the end of
chemotherapy. This case suggests that thymoma is potentially
curable with chemotherapy alone, even though cure is obtained in
the large minority of patients. It should be noted that ADOC is an
old scheme, introduced more than 10 years ago (Fornasiero et al,
1991). It could be updated by increasing the dose of some single
agents, particularly cisplatin, which is administered at lower doses
than usually scheduled in modern combination regimens. In addi-
tion, as previously suggested, the efficacy of chemotherapy can be
improved by the association of steroids (Fornasiero et al, 1991;
Tomiak and Evans, 1993). A single institution experience, very
recently published (Shin et al, 1998), showed a high response rate
(92%) and a high resection rate (69%) in 13 patients with locally
advanced thymoma submitted to a combination regimen
consisting in cisplatin (90 mg m–2), doxorubicin and cyclophos-
phamide plus oral prednisone. These results seemed to be better
than those of the present study and this may be attributable to the
higher cisplatin dose administered and the introduction of steroids
in association with chemotherapy.
In a trial recently published, Loehrer et al (1997) reported a 69%
response rate in 23 patients with limited-stage unresectable
thymoma using a combination scheme including cyclophos-
phamide, doxorubicin and cisplatin (PAC). All patients were
submitted to radiotherapy and none of them was submitted to
surgery. Either the time to treatment failure or the overall survival
were interesting. These results may suggest a combined chemo-
radiotherapy without surgery in patients with unresectable disease
‘ab initio’. It should be remembered that thymomas have a great
propensity for local relapse and on this basis we think that surgical
resection, after significant response to chemotherapy, should be
strongly advocated before radiotherapy in order to obtain the best
local control.
To conclude, the present experience confirms that the ADOC
scheme is active and manageable in the treatment of locally
advanced thymoma. The results of the present study are similar to
those obtained by another institution using the same scheme (Rea
et al, 1993). An update of this regimen, with increase of cisplatin
dose and the association of corticosteroids, can improve its effi-
cacy. The impact of preoperative chemotherapy on overall survival
cannot be assessed, due to the limited experiences up to now
published and to the uncertain natural history of many patients
with this disease. The elevated response rate obtained suggests that
this approach should be offered not only to patients with locally
advanced disease not amenable to surgery but also to those surgi-
cally resectable with a great deal of morbidity.
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